MedTrace Logo

Grape Seed Extract VS Low Level Laser Therapy for Dentin Hypersensitivity

NCT05927831 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-07-03

No results posted yet for this study

Summary

Dentin hypersensitivity (DH) is a common clinical problem frequently seen in dental patients. According to Splieth et al., the prevalence of dentin hypersensitivity is 3-98% in adult population.DH is described as a short, sharp pain or discomfort that responses to certain stimuli, typically thermal, tactile, osmotic or chemical, due to exposed dentinal surface which can be explained by the hydrodynamic theory.

The laser is a narrow, focused beam of light emitted to vaporise, fuse, melt, or seal dentinal tubules using laser heat to induce hydroxyapatite crystals for recrystallisation of the mineral component of dentine. The obliteration of dentinal tubules is caused by heat generated by laser beam which inhibits the transmission of the stimulus in the dentinal tubules.

Grape seed extract contains proanthocyanidins (PA) which is able to bind to proline-rich proteins, like collagen, and contributes in enzyme proline hydroxylase activity that is essential for the biosynthesis of collagen in the dentin. The cross-linking action of collagen fibrils in dentin also able to prevent mineral loss.

Conditions

  • Dentin Hypersensitivity

Interventions

DRUG

Grape Seed Extract

Grape seed extract will be applied in the form of a gel on the tooth surface

DEVICE

Low-level laser therapy

The device will be set at a wavelength of 810 nm, with a power output of 0.5 watts tip of diameter 300 μ in non-contact mode

Sponsors & Collaborators

  • Manipal University College Malaysia

    lead OTHER

Principal Investigators

  • Tun Yi Darren Ong · Manipal University College Malaysia

  • Li Jia Ong · Manipal University College Malaysia

  • Ju Wen Lim · Manipal University College Malaysia

  • Wei Nee Lim · Manipal University College Malaysia

  • Gursimrendeep Kaur · Manipal University College Malaysia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-15
Primary Completion
2024-01-15
Completion
2024-01-15

Countries

  • Malaysia

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05927831 on ClinicalTrials.gov